211 related articles for article (PubMed ID: 9823343)
1. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans.
Schadlu R; Maus TL; Nau CB; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1441-4. PubMed ID: 9823343
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
Maus TL; Nau C; Brubaker RF
Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954
[TBL] [Abstract][Full Text] [Related]
3. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination.
Larsson LI
Arch Ophthalmol; 2001 Apr; 119(4):492-5. PubMed ID: 11296014
[TBL] [Abstract][Full Text] [Related]
4. Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.
Kaufman PF
Arch Ophthalmol; 1999 May; 117(5):673-4. PubMed ID: 10326968
[No Abstract] [Full Text] [Related]
5. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
6. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys.
Gabelt BT; Robinson JC; Hubbard WC; Peterson CM; Debink N; Wadhwa A; Kaufman PL
Exp Eye Res; 1994 Dec; 59(6):633-44. PubMed ID: 7698258
[TBL] [Abstract][Full Text] [Related]
7. Effects of brimonidine on aqueous humor dynamics in human eyes.
Toris CB; Gleason ML; Camras CB; Yablonski ME
Arch Ophthalmol; 1995 Dec; 113(12):1514-7. PubMed ID: 7487618
[TBL] [Abstract][Full Text] [Related]
8. Selectivity of site of action and systemic effects of topical alpha agonists.
Robin AL; Burnstein Y
Curr Opin Ophthalmol; 1998 Apr; 9(2):30-3. PubMed ID: 10180510
[TBL] [Abstract][Full Text] [Related]
9. Effects of apraclonidine on aqueous humor dynamics in human eyes.
Toris CB; Tafoya ME; Camras CB; Yablonski ME
Ophthalmology; 1995 Mar; 102(3):456-61. PubMed ID: 7891985
[TBL] [Abstract][Full Text] [Related]
10. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145).
Gharagozloo NZ; Relf SJ; Brubaker RF
Ophthalmology; 1988 Sep; 95(9):1217-20. PubMed ID: 3062536
[TBL] [Abstract][Full Text] [Related]
11. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
Yuen NS; Cheung P; Hui SP
Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
[TBL] [Abstract][Full Text] [Related]
12. Aqueous humor flow in normal human eyes treated with brimonidine and dorzolamide, alone and in combination.
Tsukamoto H; Larsson LI
Arch Ophthalmol; 2004 Feb; 122(2):190-3. PubMed ID: 14769595
[TBL] [Abstract][Full Text] [Related]
13. Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Chevrier RL; Assalian A; Duperré J; Lesk MR
Ophthalmic Surg Lasers; 1999 Mar; 30(3):199-204. PubMed ID: 10100253
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine 0.2% versus apraclonidine 0.5% for prevention of intraocular pressure elevations after anterior segment laser surgery.
Chen TC; Ang RT; Grosskreutz CL; Pasquale LR; Fan JT
Ophthalmology; 2001 Jun; 108(6):1033-8. PubMed ID: 11382625
[TBL] [Abstract][Full Text] [Related]
15. Brimonidine 0.15% versus apraclonidine 0.5% for prevention of intraocular pressure elevation after anterior segment laser surgery.
Chen TC
J Cataract Refract Surg; 2005 Sep; 31(9):1707-12. PubMed ID: 16246772
[TBL] [Abstract][Full Text] [Related]
16. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients.
Toris CB; Camras CB; Yablonski ME
Am J Ophthalmol; 1999 Jul; 128(1):8-14. PubMed ID: 10482088
[TBL] [Abstract][Full Text] [Related]
17. Effects of topical adrenergic agents on prostaglandin E2-induced aqueous flare and intraocular pressure elevation in pigmented rabbits.
Nakamura-Shibasaki M; Latief MA; Ko JA; Funaishi K; Kiuchi Y
Jpn J Ophthalmol; 2016 Mar; 60(2):95-102. PubMed ID: 26832333
[TBL] [Abstract][Full Text] [Related]
18. Pupillographic, tonographic and refractive parameter changes after topical instillation of Brimonidine tartrate 0.2% in healthy subjects.
Brogliatti B; Bogetto C; Prandi B; Boles Carenini B
Acta Ophthalmol Scand Suppl; 1998; (227):34-5. PubMed ID: 9972337
[No Abstract] [Full Text] [Related]
19. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
[TBL] [Abstract][Full Text] [Related]
20. Long-term brimonidine therapy in glaucoma patients with apraclonidine allergy.
Shin DH; Glover BK; Cha SC; Kim YY; Kim C; Nguyen KD
Am J Ophthalmol; 1999 May; 127(5):511-5. PubMed ID: 10334342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
